Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. It operates through US Specialized Therapeutics, US General Medicine, and International segments. The company offers a portfolio of products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology, and anti-infective therapeutic categories. It also provides breast implants and tissue expanders; RM-131 (relamorelin), a peptide ghrelin agonist for the treatment of diabetic gastroparesis; ocular implants; and Kybella, a non-surgical treatment for submental fullness. In addition, the company develops therapies for non-alcoholic steatohepatitis and other liver diseases; treatments for neurodegenerative disorders, including Alzheimer's disease; small molecule therapeutics that target inflammatory and fibrotic diseases; and delivery system and botulinum toxin-based prescription products. It has collaboration, option, and license agreement with Lyndra, Inc.; strategic alliance and option agreement with Editas Medicine, Inc.; and licensing agreements with Assembly Biosciences, Inc. MedImmune, and Heptares Therapeutics, Ltd. The company was formerly known as Actavis plc and changed its name to Allergan plc in June 2015. Allergan plc was founded in 1983 and is headquartered in Dublin, Ireland.
Industry, Sector and Symbol
Stock Exchange NYSE
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Current SymbolNYSE:AGN
Previous SymbolNYSE:ACT
CUSIP01849010
Phone862-261-7000
Debt
Debt-to-Equity Ratio0.32
Current Ratio0.92
Quick Ratio0.78
Price-To-Earnings
Trailing P/E Ratio10.03
Forward P/E Ratio9.97
P/E Growth1.31
Sales & Book Value
Annual Sales$15.94 billion
Price / Sales3.46
Cash Flow$39.6489 per share
Price / Cash4.13
Book Value$207.19 per share
Price / Book0.79
Profitability
EPS (Most Recent Fiscal Year)$16.35
Net Income$-4,125,500,000.00
Net Margins14.50%
Return on Equity8.44%
Return on Assets5.36%
Miscellaneous
Employees17,800
Outstanding Shares337,290,000
Market Cap$55.83 billion
OptionableOptionable
Allergan (NYSE:AGN) Frequently Asked Questions
What is Allergan's stock symbol?
Allergan trades on the New York Stock Exchange (NYSE) under the ticker symbol "AGN."
How often does Allergan pay dividends? What is the dividend yield for Allergan?
Allergan declared a quarterly dividend on Friday, October 26th. Investors of record on Tuesday, November 13th will be given a dividend of $0.72 per share on Friday, December 14th. This represents a $2.88 annualized dividend and a yield of 1.76%. The ex-dividend date of this dividend is Friday, November 9th. View Allergan's Dividend History.
How will Allergan's stock buyback program work?
Allergan declared that its board has authorized a share buyback program on Tuesday, September 26th 2017, which authorizes the company to buyback $2,000,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization authorizes the company to purchase up to 2.8% of its stock through open market purchases. Stock buyback programs are usually an indication that the company's management believes its stock is undervalued.
How were Allergan's earnings last quarter?
Allergan plc (NYSE:AGN) posted its quarterly earnings data on Tuesday, October, 30th. The company reported $4.25 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $4.04 by $0.21. The firm had revenue of $3.91 billion for the quarter, compared to the consensus estimate of $3.89 billion. Allergan had a return on equity of 8.44% and a net margin of 14.50%. The business's quarterly revenue was down 3.0% compared to the same quarter last year. During the same period in the previous year, the firm posted $4.15 EPS. View Allergan's Earnings History.
When is Allergan's next earnings date?
What guidance has Allergan issued on next quarter's earnings?
Allergan issued an update on its FY18 earnings guidance on Tuesday, October, 30th. The company provided earnings per share guidance of $16.20-16.60 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $16.38. The company issued revenue guidance of $15.55-15.7 billion, compared to the consensus revenue estimate of $15.63 billion.Allergan also updated its FY 2018 guidance to $16.20-16.60 EPS.
What price target have analysts set for AGN?
22 analysts have issued 1 year target prices for Allergan's shares. Their forecasts range from $160.07 to $265.00. On average, they expect Allergan's share price to reach $211.8535 in the next year. This suggests a possible upside of 29.3% from the stock's current price. View Analyst Price Targets for Allergan.
What is the consensus analysts' recommendation for Allergan?
22 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Allergan in the last year. There are currently 4 hold ratings and 18 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Allergan.
What are Wall Street analysts saying about Allergan stock?
Here are some recent quotes from research analysts about Allergan stock:
- 1. According to Zacks Investment Research, "Allergan’s products like Botox and Linzess and new products such as Viberzi, Namzaric and Vraylar support sales. It also boasts a strong branded pipeline. Biosimilars also represent significant opportunity. However, while we remain optimistic about the company’s growth prospects, Allergan faces loss of exclusivity for many products this year including key drugs - Namenda XR and Restasis. While the first generic versions of Namenda XR and Estrace cream were launched in the first quarter, that of blockbuster dry-eye drug, Restasis is expected to be launched later this year. Sales of these products are expected to decline significantly with the introduction of generics. Also, new competition for key growth drivers, Restasis and Linzess, is an investor concern. Also, there have been concerns regarding possible new competitors to Botox, its largest product. Allergan’s shares have underperformed the industry in the past year." (10/3/2018)
- 2. Cantor Fitzgerald analysts commented, "We rate AGN Neutral and have a 12-month price target of $180. We think that Allergan is one the highest-quality and most-innovative companies in the Pharma industry. That said, we don’t see a lot of upside to consensus expectations in the near term, which is why we are on the sidelines for now. Valuation Summary We use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of $180." (9/14/2018)
- 3. Mizuho analysts commented, "We note that Mylan has invalidated Restasis patents, and Allergan mgmt. noted that two other generic manufacturers (Teva and Akorn that have not settled) could also launch Restasis generics if their applications are FDA-approved. We know that Allergan separately entered into five other generic settlements, according to its 1Q:18 10-Q filing. No news from Mylan or the others would be good news to Allergan, in our view." (7/30/2018)
Has Allergan been receiving favorable news coverage?
Press coverage about AGN stock has been trending somewhat positive on Tuesday, InfoTrie Sentiment reports. InfoTrie ranks the sentiment of press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Allergan earned a news sentiment score of 1.1 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the near term.
Who are some of Allergan's key competitors?
Some companies that are related to Allergan include Novartis (NVS), Merck & Co., Inc. (MRK), AbbVie (ABBV), Abbott Laboratories (ABT), Eli Lilly And Co (LLY), Sanofi (SNY), Novo Nordisk A/S (NVO), AstraZeneca (AZN), GlaxoSmithKline (GSK), Bristol-Myers Squibb (BMY), Bayer (BAYRY), Shire (SHPG), Celgene (CELG), Vertex Pharmaceuticals (VRTX) and Zoetis (ZTS).
Who are Allergan's key executives?
Allergan's management team includes the folowing people:
- Mr. Brenton L. Saunders, Chairman, Pres & CEO (Age 48)
- Mr. William Meury, Exec. VP & Chief Commercial Officer (Age 50)
- Dr. C. David Nicholson, Exec. VP and Chief R&D Officer (Age 63)
- Mr. Matthew M. Walsh, Exec. VP & CFO (Age 51)
- Mr. Wayne R. Swanton, Exec. VP of Global Operations (Age 50)
Who are Allergan's major shareholders?
Allergan's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Janus Henderson Group PLC (1.28%), FMR LLC (1.19%), Bank of New York Mellon Corp (1.08%), Wells Fargo & Company MN (0.52%), Jennison Associates LLC (0.53%) and Longview Partners Guernsey LTD (0.46%). Company insiders that own Allergan stock include Brent L Saunders, Chris W Bodine, Christopher J Coughlin, Joseph H Boccuzi, Maria Teresa Hilado, Matthew M Walsh, Nesli Basgoz, Paul Bisaro and William Meury. View Institutional Ownership Trends for Allergan.
Which institutional investors are selling Allergan stock?
AGN stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Janus Henderson Group PLC, Mitsubishi UFJ Trust & Banking Corp, Toronto Dominion Bank, CI Investments Inc., FIL Ltd, AXA and Wells Fargo & Company MN. View Insider Buying and Selling for Allergan.
Which institutional investors are buying Allergan stock?
AGN stock was purchased by a variety of institutional investors in the last quarter, including Sound Shore Management Inc. CT, Prudential Financial Inc., Thornburg Investment Management Inc., Assenagon Asset Management S.A., Alliancebernstein L.P., Bank of Montreal Can, Smith Asset Management Group LP and Jennison Associates LLC. Company insiders that have bought Allergan stock in the last two years include Brent L Saunders, Chris W Bodine, Christopher J Coughlin, Joseph H Boccuzi, Maria Teresa Hilado and Matthew M Walsh. View Insider Buying and Selling for Allergan.
How do I buy shares of Allergan?
Shares of AGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Allergan's stock price today?
One share of AGN stock can currently be purchased for approximately $163.87.
How big of a company is Allergan?
Allergan has a market capitalization of $55.83 billion and generates $15.94 billion in revenue each year. The company earns $-4,125,500,000.00 in net income (profit) each year or $16.35 on an earnings per share basis. Allergan employs 17,800 workers across the globe.
What is Allergan's official website?
How can I contact Allergan?
Allergan's mailing address is CLONSHAUGH BUSINESS AND TECHNOLOGY PARK COOLOCK, DUBLIN L2, D17 E400. The company can be reached via phone at 862-261-7000 or via email at [email protected]
MarketBeat Community Rating for Allergan (NYSE AGN)
MarketBeat's community ratings are surveys of what our community members think about Allergan and other stocks. Vote "Outperform" if you believe AGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AGN will underperform the S&P 500 over the long term. You may vote once every thirty days.
